These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25243813)

  • 1. BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib.
    Ranzani M; Alifrangis C; Perna D; Dutton-Regester K; Pritchard A; Wong K; Rashid M; Robles-Espinoza CD; Hayward NK; McDermott U; Garnett M; Adams DJ
    Pigment Cell Melanoma Res; 2015 Jan; 28(1):117-9. PubMed ID: 25243813
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
    Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
    JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
    Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
    Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceritinib Enhances the Efficacy of Trametinib in
    Verduzco D; Kuenzi BM; Kinose F; Sondak VK; Eroglu Z; Rix U; Smalley KSM
    Mol Cancer Ther; 2018 Jan; 17(1):73-83. PubMed ID: 29133622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
    Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
    Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.
    Menzies AM; Yeh I; Botton T; Bastian BC; Scolyer RA; Long GV
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):607-10. PubMed ID: 26072686
    [No Abstract]   [Full Text] [Related]  

  • 8. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
    Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
    [No Abstract]   [Full Text] [Related]  

  • 9. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
    Algazi AP; Esteve-Puig R; Nosrati A; Hinds B; Hobbs-Muthukumar A; Nandoskar P; Ortiz-Urda S; Chapman PB; Daud A
    Pigment Cell Melanoma Res; 2018 Jan; 31(1):110-114. PubMed ID: 28921907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L
    Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.
    Guhan SM; Shaughnessy M; Rajadurai A; Taylor M; Kumar R; Ji Z; Rashid S; Flaherty K; Tsao H
    J Invest Dermatol; 2021 Aug; 141(8):2018-2027.e4. PubMed ID: 33745909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].
    Haase O; Angün O; Grätz V; Lüttmann N; Neumann A; Zillikens D; Terheyden P
    Hautarzt; 2016 Aug; 67(8):648-52. PubMed ID: 27146499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.
    Sasaki K; Nakamura Y; Baba N; Teramoto Y; Yamamoto A
    Eur J Cancer; 2020 Nov; 139():37-40. PubMed ID: 32957012
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.
    Pigné T; Lévy M; Ducharme O; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Prey S
    Melanoma Res; 2023 Jun; 33(3):252-256. PubMed ID: 36919691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
    Vujic I; Sanlorenzo M; Posch C; Esteve-Puig R; Yen AJ; Kwong A; Tsumura A; Murphy R; Rappersberger K; Ortiz-Urda S
    Oncotarget; 2015 Jan; 6(2):969-78. PubMed ID: 25504439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
    Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.
    Akabane H; Sullivan RJ
    Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
    Maio M; Carlino MS; Joshua AM; McWhirter E; Ribas A; Ascierto PA; Miller WH; Butler MO; Ferrucci PF; Zielinski RR; Del Vecchio M; Gasal E; Ghori R; Diede SJ; Croydon E; Hamid O
    Eur J Cancer; 2022 Jan; 160():1-11. PubMed ID: 34801354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.